Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
11 nov. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, 2020
09 nov. 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the third...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
04 nov. 2020 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Moore Kuehn, PLLC Encourages Investors of CLSN, PGEN or TCMD to Contact Law Firm
03 nov. 2020 12h57 HE
|
Moore Kuehn
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible...
Celsion Corporation Issues Letter to Stockholders
12 oct. 2020 08h00 HE
|
Celsion CORP
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study
08 sept. 2020 08h35 HE
|
Celsion CORP
Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,...
Celsion Corporation Restructures its Strategic Loan Facility
02 sept. 2020 08h00 HE
|
Celsion CORP
Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization New Agreement Ensures A Strong Balance Sheet and Additional...
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
14 août 2020 08h00 HE
|
Celsion CORP
Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival;Data Maturity at Issue Conference Call...
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
27 juil. 2020 08h30 HE
|
Celsion CORP
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for...
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
14 juil. 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...